Other medications

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2